Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Prostate cancer progression and treatment resistance are linked to epigenetic reprogramming.
• The roles of EHMT1 (GLP) and EHMT2 (G9A) histone methyltransferases in prostate cancer are not well understood.

Purpose of the Study:

• To investigate the function and regulation of EHMT1 and EHMT2 in prostate cancer.
• To explore the therapeutic potential of targeting EHMT1/2 and their associated epigenetic modifications.

Main Methods:

• Comprehensive molecular investigations including protein analysis and functional assays.
• In vitro and in vivo studies using cell lines and animal models.
• Small-molecule inhibitors targeting EHMT1/2 enzymatic activity.

Main Results:

• EHMT1 and EHMT2 activate oncogenic transcription programs in prostate cancer cells.
• Silencing EHMT1/2 or inhibiting their activity reduces cancer cell proliferation and metastasis.
• Dual-lysine demethylation of EHMT1 at K450/K451 expands its chromatin binding, inducing oncogenic reprogramming.

Conclusions:

• EHMT1/2 proteins are key drivers of prostate cancer progression through transcriptional activation.
• Dual-lysine demethylation of EHMT1 acts as a molecular switch for oncogenic reprogramming.
• Targeting EHMT1/2 and their demethylation pathways presents a promising therapeutic strategy for prostate cancer.